Annals of Oncology 13:1356-1363, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma
Departments of 1 Nuclear Medicine, 2 Hematology, 3 Oncology, 4 Microbiology and 5 Pathology, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
Received 24 January 2002; revised 12 March 2002; accepted 27 March 2002
Background:
Less than half of all patients with aggressive non-Hodgkin’s lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.
Patients and methods:
Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [18F]FDG-PET scan at midtreatment. Presence or absence of abnormal [18F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan–Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [18F]FDG-PET findings on PFS and OS.
Results:
At midtreatment, 33 patients showed persistent abnormal [18F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [18F]FDG-PET findings and PFS (P <1 x 10–5) and OS (P <1 x 10–5). In multivariate analysis, [18F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10–7) and OS (P <9 x 10–6) than the IPI (P <0.11 and P <0.03, respectively).
Conclusions:
Early restaging [18F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.
Key words: [18F]FDG-PET, non-Hodgkin’s lymphoma, therapy monitoring
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review J. Clin. Oncol., April 10, 2009; 27(11): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, C. Gisselbrecht, C. Lin, C. Copie-Bergman, K. Belhadj, T. El Gnaoui, I. Gaillard, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria Ann. Onc., March 1, 2009; 20(3): 503 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Noy, H. Schoder, M. Gonen, M. Weissler, K. Ertelt, C. Cohler, C. Portlock, P. Hamlin, and H. W. D. Yeung The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL) Ann. Onc., March 1, 2009; 20(3): 508 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Han, M. P. Escalon, B. Hsiao, A. Serafini, and I. S. Lossos High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens Ann. Onc., February 1, 2009; 20(2): 309 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Suh, Y.-K. Kang, J.-L. Roh, M. R. Kim, J. S. Kim, J. Huh, J. H. Lee, Y. J. Jang, and B.-J. Lee Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck J. Nucl. Med., November 1, 2008; 49(11): 1783 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Bakker and G. W. van Imhoff Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematologica, November 1, 2007; 92(11): 1447 - 1450. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber 18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative? J. Nucl. Med., October 1, 2007; 48(10): 1580 - 1582. [Full Text] [PDF]
|
|
|
|
|
|
C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis J. Nucl. Med., October 1, 2007; 48(10): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Advani, L. Maeda, P. Lavori, A. Quon, R. Hoppe, S. Breslin, S. A. Rosenberg, and S. J. Horning Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease J. Clin. Oncol., September 1, 2007; 25(25): 3902 - 3907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al. Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Zinzani, M. Tani, R. Trisolini, S. Fanti, V. Stefoni, M. Alifano, P. Castellucci, G. Musuraca, G. Dalpiaz, L. Alinari, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma Haematologica, June 1, 2007; 92(6): 771 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al. Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma Haematologica, June 1, 2007; 92(6): 778 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Strobel, N. Schaefer, C Renner, P Veit-Haibach, D Husarik, A. Koma, and T. Hany Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Ann. Onc., April 1, 2007; 18(4): 658 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Brepoels, S. Stroobants, P. Vandenberghe, K. Spaepen, P. Dupont, J. Nuyts, G. Bormans, L. Mortelmans, G. Verhoef, and C. De Wolf-Peeters Effect of Corticosteroids on 18F-FDG Uptake in Tumor Lesions After Chemotherapy J. Nucl. Med., March 1, 2007; 48(3): 390 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood, March 1, 2007; 109(5): 1857 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al. Revised Response Criteria for Malignant Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Blodgett, C. C. Meltzer, and D. W. Townsend PET/CT: Form and Function Radiology, February 1, 2007; 242(2): 360 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Kasamon, R. J. Jones, and R. L. Wahl Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al. Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Res., November 15, 2006; 66(22): 11055 - 11061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Ceresoli, A. Chiti, P. A. Zucali, M. Rodari, R. F. Lutman, S. Salamina, M. Incarbone, M. Alloisio, and A. Santoro Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose J. Clin. Oncol., October 1, 2006; 24(28): 4587 - 4593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients Ann. Onc., August 1, 2006; 17(8): 1296 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Liedtke, P. A. Hamlin, C. H. Moskowitz, and A. D. Zelenetz Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population Ann. Onc., June 1, 2006; 17(6): 909 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Juweid and B. D. Cheson Positron-Emission Tomography and Assessment of Cancer Therapy N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507. [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Sehn Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 295 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hutchings, A. Loft, M. Hansen, L. M. Pedersen, T. Buhl, J. Jurlander, S. Buus, S. Keiding, F. D'Amore, A.-M. Boesen, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood, January 1, 2006; 107(1): 52 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Milleron, V. Westeel, E. Quoix, D. Moro-Sibilot, D. Braun, B. Lebeau, A. Depierre, and for the French Thoracic Cooperative Group Complete Response Following Preoperative Chemotherapy for Resectable Non-Small Cell Lung Cancer: Accuracy of Clinical Assessment Using the French Trial Database Chest, September 1, 2005; 128(3): 1442 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Mikhaeel, M. Hutchings, P. A. Fields, M. J. O'Doherty, and A. R. Timothy FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma Ann. Onc., September 1, 2005; 16(9): 1514 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Haioun, E. Itti, A. Rahmouni, P. Brice, J.-D. Rain, K. Belhadj, P. Gaulard, L. Garderet, E. Lepage, F. Reyes, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome Blood, August 15, 2005; 106(4): 1376 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schoder, A. Noy, M. Gonen, L. Weng, D. Green, Y. E. Erdi, S. M. Larson, and H. W.D. Yeung Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., July 20, 2005; 23(21): 4643 - 4651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Juweid and B. D. Cheson Role of Positron Emission Tomography in Lymphoma J. Clin. Oncol., July 20, 2005; 23(21): 4577 - 4580. [Full Text] [PDF]
|
|
|
|
|
|
J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hutchings, N. G. Mikhaeel, P. A. Fields, T. Nunan, and A. R. Timothy Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma Ann. Onc., July 1, 2005; 16(7): 1160 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Horning In Reply: J. Clin. Oncol., May 1, 2005; 23(13): 3162 - 3163. [Full Text] [PDF]
|
|
|
|
|
|
H. Kondoh, M. E. Lleonart, J. Gil, J. Wang, P. Degan, G. Peters, D. Martinez, A. Carnero, and D. Beach Glycolytic Enzymes Can Modulate Cellular Life Span Cancer Res., January 1, 2005; 65(1): 177 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamane, O. Daimaru, S. Ito, K. Yoshiya, T. Nagata, S. Ito, and H. Uchida Decreased 18F-FDG Uptake 1 Day After Initiation of Chemotherapy for Malignant Lymphomas J. Nucl. Med., November 1, 2004; 45(11): 1838 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Hillner, R. Tunuguntla, and M. Fratkin Clinical Decisions Associated With Positron Emission Tomography in a Prospective Cohort of Patients With Suspected or Known Cancer at One United States Center J. Clin. Oncol., October 15, 2004; 22(20): 4147 - 4156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Toner Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use J. Clin. Oncol., October 1, 2004; 22(19): 3842 - 3845. [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Cheson What Is New in Lymphoma? CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bendandi, S. A. Pileri, and P. L. Zinzani Challenging paradigms in lymphoma treatment Ann. Onc., May 1, 2004; 15(5): 703 - 711. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Balzarotti, M. Magagnoli, and A. Santoro Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true? Ann. Onc., July 1, 2003; 14(7): 1155 - 1156. [Full Text] [PDF]
|
|
|
|
|
|
K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Maertens, G. Bormans, J. Thomas, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Blood, July 1, 2003; 102(1): 53 - 59. [Abstract] [Full Text] [PDF]
|
|